Prescient Therapeutics (ASX:PTX) Research & Development : A$7.82 Mil (TTM As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Prescient Therapeutics's Research & Development for the six months ended in Dec. 2023 was A$4.05 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$7.82 Mil.

Prescient Therapeutics Research & Development Historical Data

The historical data trend for Prescient Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Research & Development Chart

Prescient Therapeutics Annual Data

Trend

Jun13

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Research & Development

Get a 7-Day Free Trial

3.68

2.76

2.50

3.40

6.22

Prescient Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Research & Development	Get a 7-Day Free Trial															1.61	1.79	2.45	3.77	4.05

Prescient Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$7.82 Mil.

Prescient Therapeutics (ASX:PTX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Prescient Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics (ASX:PTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.ptxtherapeutics.com

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines